PTC Therapeutics Gains Positive Opinion for Sephience™
In a significant breakthrough for the phenylketonuria (PKU) community, PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion regarding the marketing authorization for Sephience™ (sepiapterin). This oral formulation is aimed at alleviating the challenges faced by both children and adults suffering from PKU.
A Lifeline for PKU Patients
This favorable opinion marks a pivotal moment for the PKU patient community, particularly those in Europe who currently face limited treatment options. Matthew B. Klein, M.D., CEO of PTC Therapeutics, expressed optimism about the news, emphasizing the urgent medical needs these patients have. “We look forward to the European Commission adopting this positive opinion and starting the launch,” Klein stated, highlighting the gathered data supporting Sephience’s efficacy in lowering phenylalanine levels while offering dietary flexibility for even the most severely affected patients.
Elevated Plans for European Launch
Preparations for the launch of Sephience in Europe are moving swiftly, with a focus on pivotal markets such as Germany. PTC is committed to ensuring that named patient access is established immediately, bringing the new treatment to those in urgent need.
The European Commission is expected to finalize the marketing authorization for Sephience within two months, representing a promising step for all member states of the European Union, as well as in countries like Iceland, Norway, and Liechtenstein.
Regulatory Landscape in the U.S. and Beyond
Meanwhile, in the United States, the New Drug Application (NDA) for sepiapterin is currently under review by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) target action date is set for July 29, 2025. Additionally, PTC is pursuing regulatory approvals in several countries, including Japan and Brazil, expanding the treatment's global reach.
Understanding Sephience™ (sepiapterin)
Sephience is engineered to enhance the action of the phenylalanine hydroxylase (PAH) enzyme through a dual mechanism of action. The formulation acts as a precursor swiftly transforming into tetrahydrobiopterin (BH4), essential for PAH function. Additionally, Sephience serves as a pharmacological chaperone, correcting the misfolding of PAH to optimize its function. This innovative approach significantly reduces blood phenylalanine levels and shows promise across a spectrum of PKU patients.
Insights on Phenylketonuria (PKU)
Phenylketonuria is a rare inherited metabolic disorder that primarily affects the neurological function due to a deficiency in the enzyme necessary to metabolize phenylalanine, an amino acid present in various foods. Without proper management, elevated levels of phenylalanine can lead to severe consequences, including permanent cognitive impairment and other neurological issues. Early diagnosis is crucial, as newborns do not exhibit symptoms but suffer irreversible damage if high phenylalanine levels persist.
About PTC Therapeutics, Inc.
PTC Therapeutics is on a mission to innovate and commercialize specialized medicines that cater to the needs of individuals with rare disorders. The company leverages its expertise in developing therapies that significantly improve the quality of life for those living with challenging health conditions. To discover more about PTC and its initiatives, visit their official website or engage with them on social media platforms.
For More Information
Investors:
Ellen Cavaleri
+1 (615) 618-6228
Media:
Jeanine Clemente
+1 (908) 912-9406
Frequently Asked Questions
What is Sephience™ used for?
Sephience™ is designed for the treatment of phenylketonuria (PKU) in both children and adults, helping to lower phenylalanine levels.
What does the CHMP opinion signify?
The positive opinion from CHMP is a crucial step towards securing marketing authorization in Europe, indicating endorsement of Sephience's efficacy and safety.
How does Sephience work?
Sephience acts as a dual mechanism treatment by enhancing the activity of the PAH enzyme and corrects misfolding to improve function.
What are the implications of the European Commission's decision?
If ratified, Sephience will be available to patients across the EU and select additional European countries, broadening access for those in need.
When is the expected U.S. approval date for Sephience?
The PDUFA target action date for the NDA submission in the U.S. is July 29, 2025, indicating when a decision is anticipated.
